mepolizumab CRSwNP
Selected indexed studies
- Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia. (Rhinology, 2024) [PMID:39058315]
- Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents' efficacy. (Int Forum Allergy Rhinol, 2024) [PMID:37394893]
- One year mepolizumab outcomes in severe, uncontrolled CRSwNP: a real-life study. (Rhinology, 2025) [PMID:40631514]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison. (2024) pubmed
- Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis. (2023) pubmed
- Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents' efficacy. (2024) pubmed
- Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps. (2025) pubmed
- Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia. (2024) pubmed
- One year mepolizumab outcomes in severe, uncontrolled CRSwNP: a real-life study. (2025) pubmed
- Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy? (2024) pubmed
- Mepolizumab in severe uncontrolled CRSwNP: a real-life multicentre study in Northeast Italy. (2025) pubmed
- The Effects of Mepolizumab on CRSwNP: Real-Life Evidence. (2024) pubmed
- Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma. (2025) pubmed